-+ 0.00%
-+ 0.00%
-+ 0.00%

Galectin says belapectin cuts new varices in NAVIGATE MASH cirrhosis trial analysis

PUBT·05/27/2026 12:02:05
Listen to the news
Galectin says belapectin cuts new varices in NAVIGATE MASH cirrhosis trial analysis
  • Galectin Therapeutics released new analyses from its NAVIGATE trial of belapectin, presented at EASL 2026 in Barcelona on May 27-30.
  • Results were already presented, including an oral session and a TOP Poster focused on advanced MASH cirrhosis with portal hypertension.
  • Belapectin was linked to fewer new esophageal varices in higher-risk patients, supporting a potential role in slowing disease progression.
  • Analyses also pointed to improved portal-hypertension risk status, reinforcing belapectin’s positioning as a disease-modifying candidate in an area with no approved options.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270800PRIMZONEFULLFEED9726489) on May 27, 2026, and is solely responsible for the information contained therein.